Videos

Neratinib for Metastatic HER2+ Breast Cancer and Brain Metastases

A neuro-oncologist explains the prevalence of leptomeningeal metastases in HER2+ breast cancer and her preferred method of treatment.

Sara Hurvitz, MD;Stefania Maraka, MD;Ruta Rao, MD

Maintenance Therapy Duration and Considerations for Treatment Interruption

Oncologists debate the use of neratinib for metastatic HER2+ breast cancer treatment in the context of the HER2CLIMB clinical trial data on tucatinib.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

Treatment for Cisplatin-Ineligible Patients with High PD-L1 Expression

Experts comment on the typical urothelial cancer maintenance therapy duration in their practice, and situations in which they might consider interrupting treatment while maintaining patient response.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

Maintenance Therapy Strategies for Transplant Eligible Multiple Myeloma

Petros Grivas, MD, PhD, shares a clinical scenario of a cisplatin-ineligible patient with high PD-L1 expression and lymph node metastases, and experts weigh in on recommended treatment options.

Sagar Lonial, MD;Nisha Joseph, MD;Jonathan L. Kaufman, MD;Ajay K. Nooka, MD

Matthew Krebs, MB, PhD, Reviews the Next Steps for Subcutaneous Amivantamab in Solid Tumors

Drs Ajay Nooka and Jonathan Kaufman discuss maintenance and consolidation treatment strategies for transplant eligible multiple myeloma.

Matthew Krebs, MB, PhD

Treatment Approaches for Patients with Newly Diagnosed Multiple Myeloma

Matthew Krebs, MB, PhD, spoke about how subcutaneous amivantamab can best be utilized in future clinical trials.

Sagar Lonial, MD;Nisha Joseph, MD;Jonathan L. Kaufman, MD;Ajay K. Nooka, MD

Advice for Community Oncologists Treating Renal Cell Carcinoma

Experts discuss how they select a treatment regimen for a newly diagnosed multiple myeloma patient, and how they measure a successful treatment response.

Thomas E. Hutson, DO, PharmD;Scott S. Tykodi, MD, PhD

Peter Humphrey, MD, PhD, Discusses Current Role of Pathology in RCC

Dr Scott Tykodi provides advice for community oncologists managing patients with renal cell carcinoma.

Peter Humphrey MD, PhD

Nicolas Girard, MD, on the Safety Profile of Nivolumab Plus Chemotherapy in Resectable NSCLC

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about the role of pathology in renal cell carcinoma.

Nicolas Girard, MD

May 7th 2022

Nicolas Girard, MD, speaks with CancerNetwork® about the updated safety findings of nivolumab and chemotherapy in resectable non–small cell lung cancer.

David M. O’Malley, MD, Reviews the Benefit of Pembrolizumab for Endometrial Cancer

David O'Malley, MD, The Ohio State University Comprehensive Cancer Center

Frontline Treatment Options for Early-Stage HER2+ Breast Cancer

David M. O’Malley, MD, spoke about unmet needs of patients with advanced microsatellite instability–¬high or mismatch repair deficient endometrial carcinoma and the clinical benefit pembrolizumab provides.

Sarah M. Tolaney, MD, MPH

Goals of Care for Patients with Early-Stage versus Advanced or Metastatic HER2+ Breast Cancer

Sarah M. Tolaney, MD, MPH, reviews the treatment options for patients with early-stage HER2+ breast cancer in the frontline setting.

Sarah M. Tolaney, MD, MPH

Use of Inotuzumab for ALL in the Frontline Setting

Sarah M. Tolaney, MD, MPH, provides an overview of how goals of care and prognosis differ between patients with early-stage HER2+ breast cancer and advanced or metastatic HER2+ breast cancer.

Steven Frommeyer;Nikesh Shah, MD;Somedeb Ball, MD;Reem Akel, MD;Meghan Thompson, MD;Varun Narendra, MD;Xiaoli Mi, MD

Team Introductions: The Moffitt Marrowvingians vs The Memorial Sloan-Kettering Mavericks

Nikesh Shah, MD, presents a trial published in Lancet Oncology in 2018 on the use of inotuzumab plus mini-CVD in the frontline setting for older patients with ALL.

Steven Frommeyer;Nikesh Shah, MD;Somedeb Ball, MD;Reem Akel, MD;Varun Narendra, MD;Xiaoli Mi, MD;Meghan Thompson, MD

Role of Immunotherapy in Newly Diagnosed NSCLC

Steven Frommeyer kicks off a new and exciting competitive series from CancerNetwork® and introduces the first 2 teams.

Charu Aggarwal, MD, MPH;Benjamin P. Levy, MD;Harvey I. Pass, MD;Heather Wakelee, MD

Patient Profile 1: Stage IIB NSCLC With High PD-L1 Expression

A broad discussion on the role of immunotherapy in newly diagnosed NSCLC in both the neoadjuvant and adjuvant settings.

Charu Aggarwal, MD, MPH;Benjamin P. Levy, MD;Harvey I. Pass, MD;Heather Wakelee, MD

Nina Shah, MD, Shares Key Takeaways From Phase 2 KarMMa Trial Sub-Analysis of Ide-Cel in R/R Multiple Myeloma

Shared insight on a patient profile of newly diagnosed non–small cell lung cancer with high PD-L1 expression and no driver mutation.

Nina Shah, MD

Catherin Watson, MD, Assesses the Future of Genetic Testing in Ovarian Cancer

Nina Shah, MD, spoke about her key takeaways from a sub-analysis of the phase 2 KarMMa trial assessing correlates of complete response among those treated with idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Catherine Watson, MD

Common Adverse Events with Single-Agent or Combination Therapy

At SGO 2022, Catherine Watson, MD, spoke about how to encourage patients with ovarian cancer to seek genetic testing.

David Aggen, MD, PhD;Robert S. Alter, MD;Arnab Basu, MD, MPH, FACP;Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center;Mehmet Asim Bilen, MD

Safety and Efficacy Data: The CLEAR Trial

Mehmet Asim Bilen, MD, provides an overview of commonly observed adverse events in patients with metastatic RCC receiving single-agent or combination therapy.

David Aggen, MD, PhD;Robert S. Alter, MD;Arnab Basu, MD, MPH, FACP

GALAXY Study Enrollment and Patient Cohorts

David Aggen, MD, PhD, reviews data from the CLEAR trial, which assessed the safety and efficacy of lenvatinib/pembrolizumab versus sunitinib.

Stacey A. Cohen, MD;Mark Lewis, MD

Introduction and CIRCULATE-Japan Overview

Drs Cohen and Lewis review the GALAXY enrollment strategy and describe the various colorectal cancer patient cohorts in the study.

Stacey A. Cohen, MD;Mark Lewis, MD

The Role of Photopheresis for GVHD Following Progression

Stacey A. Cohen, MD, and Mark Lewis, MD, introduce the 2022 ASCO GI abstract, “Association of Circulating Tumor DNA Dynamics With Clinical Outcomes in the Adjuvant Setting for Patients With Colorectal Cancer From an Observational GALAXY Study in CIRCULATE-Japan.”

John F. D. Dipersio, MD, PhD;Yi-Bin Chen, MD;Hannah Choe, MD;Pashna N. Munshi, MD

Clinical Scenario 2: Steroid-Refractory Chronic GVHD

A panel of experts shares key insights into the role of photopheresis when patients with GVHD progress following initial treatment and emphasize its potential for patients with high skin involvement.

John F. D. Dipersio, MD, PhD;Yi-Bin Chen, MD;Hannah Choe, MD;Pashna N. Munshi, MD

Sam Klempner, MD, Looks at Broad Use of ctDNA in Oncology

Key opinion leaders in stem cell transplant and cellular immunotherapy review therapeutic considerations for the clinical scenario of a patient with steroid-refractory chronic GVHD.

Sam Klempner, MD